Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease.

[1]  D. Wood,et al.  Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. , 2020, JAMA cardiology.

[2]  D. Dudek,et al.  Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. , 2019, European heart journal.

[3]  M. Keltai,et al.  Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial. , 2019, Journal of the American College of Cardiology.

[4]  Á. Avezum,et al.  Complete Revascularization with Multivessel PCI for Myocardial Infarction. , 2019, The New England journal of medicine.

[5]  Sunil V. Rao,et al.  Predictors and Outcomes of Staged Versus One-Time Multivessel Revascularization in Multivessel Coronary Artery Disease: Insights From the VA CART Program. , 2018, JACC: Cardiovascular Interventions.

[6]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[7]  H. Thiele,et al.  One‐Year Outcomes after PCI Strategies in Cardiogenic Shock , 2018, The New England journal of medicine.

[8]  G. Dangas,et al.  Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease: Meta-Analysis and Meta-Regression of Randomized Trials. , 2018, JACC. Cardiovascular interventions.

[9]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[10]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[11]  H. Thiele,et al.  PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock , 2017, The New England journal of medicine.

[12]  G. Stefanini,et al.  Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. , 2017, The New England journal of medicine.

[13]  L. Køber,et al.  Fractional Flow Reserve–Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment–Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease Treatment , 2017, Circulation. Cardiovascular interventions.

[14]  S. Robinson,et al.  Culprit Vessel Versus Multivessel Versus In-Hospital Staged Intervention for Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: Stratified Analyses in High-Risk Patient Groups and Anatomic Subsets of Nonculprit Disease. , 2017, JACC. Cardiovascular interventions.

[15]  H. Swanton,et al.  Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study , 2016, Journal of Cardiovascular Magnetic Resonance.

[16]  L. Køber,et al.  Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial , 2015, The Lancet.

[17]  C. Terkelsen,et al.  Influence of multivessel disease with or without additional revascularization on mortality in patients with ST-segment elevation myocardial infarction. , 2015, American heart journal.

[18]  H. Suryapranata,et al.  Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials , 2015, Heart.

[19]  H. Swanton,et al.  Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease , 2015, Journal of the American College of Cardiology.

[20]  S. Umemura,et al.  Morphological features of non-culprit plaques on optical coherence tomography and integrated backscatter intravascular ultrasound in patients with acute coronary syndromes. , 2015, European heart journal cardiovascular Imaging.

[21]  Manesh R. Patel,et al.  Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. , 2014, JAMA.

[22]  M. Valgimigli,et al.  Long‐term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit‐only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  C. Berry,et al.  Randomized trial of preventive angioplasty in myocardial infarction. , 2013, The New England journal of medicine.

[24]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[25]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[26]  Sanjay Kaul,et al.  Non-inferiority study design: lessons to be learned from cardiovascular trials. , 2012, European heart journal.

[27]  J. Ottervanger,et al.  Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial , 2012, Netherlands Heart Journal.

[28]  D. Holmes,et al.  Clinical ResearchInterventional CardiologyCulprit Vessel Only Versus Multivessel and Staged Percutaneous Coronary Intervention for Multivessel Disease in Patients Presenting With ST-Segment Elevation Myocardial Infarction: A Pairwise and Network Meta-Analysis , 2011 .

[29]  B. Gersh,et al.  Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. , 2011, Journal of the American College of Cardiology.

[30]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[31]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[32]  G. Sangiorgi,et al.  A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up , 2009, Heart.

[33]  I. White.  Sample Size Calculations in Clinical Research , 2008 .

[34]  B. Gersh,et al.  Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. , 2007, European heart journal.

[35]  S. Solomon,et al.  Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2006, American heart journal.

[36]  D. Dudek,et al.  The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. , 2004, The Journal of invasive cardiology.

[37]  C. W. Barth,et al.  Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. , 2004, American heart journal.

[38]  P. Bacchetti,et al.  Sample size calculations in clinical research. , 2002, Anesthesiology.

[39]  W. O’Neill,et al.  Multiple complex coronary plaques in patients with acute myocardial infarction. , 2000, The New England journal of medicine.

[40]  C. Farrington,et al.  Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. , 1990, Statistics in medicine.

[41]  W. Conover.  Statistical Methods for Rates and Proportions , 1974 .

[42]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[43]  G. Thanassoulis,et al.  Fractional Flow Reserve–Guided Multivessel Angioplasty in Myocardial Infarction. , 2017, The New England journal of medicine.

[44]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[45]  Samin K. Sharma,et al.  Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. , 2010, JACC. Cardiovascular interventions.